CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for J-Pharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

J-Pharma Co Ltd
Leading Venture Plaza 1
75-1, Ono-cho, Tsurumi-ku
Phone: +81 364324270p:+81 364324270 MINATO-KU, TKY  105-0013  Japan Ticker: 520A520A
Business Summary
J-Pharma Co Ltd is a Japan-based company engaged primarily in pharmaceutical research and development, grounded in drug discovery targeting solute carrier (SLC) transporters. The Company operates the research-driven drug discovery business segment. The Company focuses on the L-type amino acid transporter 1 (LAT1), originally identified by its founders, and promotes the development of LAT1 inhibitors that address the unmet medical needs of patients with cancers and autoimmune diseases who have limited treatment options. The Company’s clinical development pipeline consists of Nanvuranlat (JPH203) and JPH034.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20253/31/2025Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director MasuhiroYoshitake
Chief Financial Officer, Director NorihiroAshida
Independent Director ShinichiroKomoto
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 16 (As of 1/31/2026)
Outstanding Shares: 17,829,610 (As of 12/31/2025)
Stock Exchange: TYO
Fax Number: +81 364324271


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, February 27, 2026